Trial intelligence / Profile preview

DGPR1008 for intraoperative imaging in prostate cancer (Phase II)

CTR20260305Phase 2Active

Sponsor
Xindou Biotechnology
Start
Mar 2026
Modality
Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries
1
01

Overview

A Phase 2 trial of DGPR1008 in prostate cancer (PCa), sponsored by Xindou Biotechnology. Started Mar 2026; status: active.

02

Drugs

DGPR1008
03

Conditions

prostate cancer (PCa)

Beyond the preview

Go deeper on CTR20260305.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20260305.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call